Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
393.6 SEK | +1.76% | +2.39% | +36.95% |
Apr. 25 | Mycronic AB has Received Replacement Order for A Prexision 80 Evo from an Existing Customer in Asia | CI |
Apr. 18 | Transcript : Mycronic AB, Q1 2024 Earnings Call, Apr 18, 2024 |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past twelve months, EPS forecast has been revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With a 2024 P/E ratio at 24.72 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Semiconductor Equipment & Testing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+36.95% | 3.49B | B- | ||
+24.19% | 354B | B | ||
+18.04% | 119B | B | ||
+38.63% | 106B | B+ | ||
+11.80% | 19.87B | C+ | ||
+9.63% | 19.8B | B+ | ||
+39.48% | 10.32B | B+ | ||
+36.46% | 9.88B | B | ||
-2.68% | 7.96B | C+ | ||
-22.43% | 6.13B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MYCR Stock
- Ratings Mycronic AB